[HTML][HTML] COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …
variable disease severity and a bimodal course characterized by acute respiratory viral …
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …
STAT) pathway has become recognized as a central mediator of widespread and varied …
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
[HTML][HTML] Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Background Coronavirus disease 2019 (COVID-19) has affected> 210 million people
worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since …
worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since …
Coronavirus disease-2019 in the immunocompromised host
CD Bertini, F Khawaja, A Sheshadri - Infectious Disease Clinics, 2024 - id.theclinics.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus that
originated in Wuhan, China in 2019. Since that time, SARS-CoV-2 has been responsible for …
originated in Wuhan, China in 2019. Since that time, SARS-CoV-2 has been responsible for …
IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how?
MA Matthay, AF Luetkemeyer - JAMA, 2021 - jamanetwork.com
(IL-6), based on the hypothesis that SARS-CoV-2 creates injury to the lung and other organs
in part through activation of cytokine and downstream proinflammatory networks. While …
in part through activation of cytokine and downstream proinflammatory networks. While …
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis
RY Limen, R Sedono, A Sugiarto… - Expert Review of Anti …, 2022 - Taylor & Francis
Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …
their ability in restraining immune response, yet the corroboration regarding their advantage …
Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19
DP Smith, O Oechsle, MJ Rawling, E Savory… - Frontiers in …, 2021 - frontiersin.org
The onset of the 2019 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic necessitated the identification of approved drugs to treat the disease, before the …
pandemic necessitated the identification of approved drugs to treat the disease, before the …
Immune-guided therapy of COVID-19
Vaccination has been a game changer in our efforts to address the coronavirus disease
2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for …
2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for …